This peer-reviewed study demonstrates that adjunctive thymosin beta-4 (TB4) combined with standard antibiotic therapy (ciprofloxacin) not only reduces bacterial keratitis severity and accelerates wound healing, but critically also promotes corneal nerve regeneration and restores visual function—outcomes that represent significant clinical advantages beyond infection control alone. The research fills a previously unexplored gap by quantifying TB4’s impact on two often-neglected but essential determinants of long-term patient outcomes: sensory nerve recovery and functional vision restoration. For practitioners, this represents compelling evidence that TB4 adjunctive therapy addresses the full spectrum of corneal infection recovery, not just pathogen elimination.
For your business
TB4 adjunctive therapy may support nerve regeneration and visual recovery post-keratitis, beyond infection control alone.